SCHEMBL6765256

SCHEMBL6765256

CSc1ccc(CNc2ccc3oc4ccc(F)cc4c3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.53
MAPT P10636 4/20 0.53
CYP1A2 P05177 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
NPC1 O15118 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 1/20 0.53
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
RECQL P46063 1/20 0.49
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP10 Q14694 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
USP13 Q92995 1/20 0.39
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484551 0.88 USP10 (0.48) HPGDUSP10PIK3C3USP13LMNA
SCHEMBL6480348 0.86 MEN1 (0.56) RAB9AMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL6493222 0.85 MAPT (0.48) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL6481651 0.83 EGFR (0.43) RAB9ACYP1A2CYP2C9CYP2C19NPC1
SCHEMBL6481101 0.83 MEN1 (0.45) RAB9AMAPTMEN1KMT2ARECQL
SCHEMBL6496615 0.82 MAOB (0.49) MEN1KMT2AHPGDMAOBCA12
SCHEMBL6768807 0.82 ALDH1A1 (0.44) RAB9AMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL6482939 0.82 CA1 (0.44) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL6491163 0.82 RAB9A (0.53) RAB9AMAPTNPC1MEN1KMT2A
SCHEMBL6482716 0.81 CLK1 (0.41) HPGDUSP10PIK3C3USP13CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 RAB9A 4535/4885MAPT 2337/4885CYP1A2 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.